Skip to main content
Top

Development of a CT-less SPECT Acquisition Protocol for Kidney Dosimetry in 177Lu-PSMA-617 Radioligand Therapy

  • Open Access
  • 20-03-2025
  • Research Article
Published in:

Abstract

Purpose

Targeted radioligand therapy of metastatic castration-resistant prostate cancer (mCRPC) with 177Lu-PSMA (RLT) requires sufficient dose monitoring of the kidneys. Currently, dosimetry using SPECT/CT-imaging is the most preferred method. However, SPECT/CT is a time-consuming procedure and comprises additional radiation exposure to the patient. Moreover, not every therapeutic nuclear medicine facility has access to SPECT/CT. Therefore, the aim of this study was to develop a new procedure of kidney dosimetry without the use of SPECT/CT and evaluate this method in a large cohort of patients with mCRPC undergoing RLT.

Procedures

A dedicated torso phantom with kidneys filled with a solution of 177Lu-PSMA was used for quantitative calibration of a SPECT-camera. The calculated sensitivity was adapted according to the individual attenuation of the patient in four directions from the kidney surface to the body surface (ventral, dorsal, left and right) obtained from a previously performed CT. A total of 196 patients undergoing 926 cycles of 177Lu-PSMA therapy were retrospectively analyzed. Abdominal SPECT was performed 24, 48 and 72 h after administration of 177Lu-PSMA including scatter and dead-time correction in every patient. Kidney dose was calculated using an individual attenuation-based procedure and compared to values from international literature.

Results

Volumes of interest of the kidneys were drawn in the three sequential SPECT-images to calculate intra-renal effective half-life. Absolute quantification of activity in the kidneys was accomplished obtaining a patient individual sensitivity based on the individual attenuation in the patient. Kidney dose was then calculated applying a bi-exponential time activity curve in Microsoft EXCEL. Mean kidney dose per administered activity was 0.54 (± 0.26) Gy/GBq.

Conclusions

With the presented procedure a reliable kidney dosimetry is possible without the use of SPECT/CT. Facilities without SPECT/CT are therefore able to perform an adequate kidney dosimetry without additional radiation exposure for the patient.
Title
Development of a CT-less SPECT Acquisition Protocol for Kidney Dosimetry in 177Lu-PSMA-617 Radioligand Therapy
Authors
Christian Happel
Larissa Völler
Benjamin Bockisch
Daniel Groener
Britta Leonhäuser
Frank Grünwald
Amir Sabet
Publication date
20-03-2025
Publisher
Springer International Publishing
Published in
Molecular Imaging and Biology / Issue 3/2025
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-025-01998-2
This content is only visible if you are logged in and have the appropriate permissions.

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

1.75 AMA PRA Category 1 Credits

Explore using biomarker testing to interpret results and guide treatment strategies through an interactive patient simulation and unique educational escape rooms.

This content is intended for healthcare professionals outside of the UK.

Independent Medical Education Grant:
  • Lilly
Learn more TODO (Link opens in a new window)

How can you integrate PET into your practice? (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)™

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Independent Medical Education Grant:
  • Lilly
Learn more TODO (Link opens in a new window)
Image Credits
Alzheimer’s disease in the biomarker era: preparing the multidisciplinary care team/© Springer Healthcare IME, Navigating neuroimaging in Alzheimer’s care: Practical applications and strategies for integration/© Springer Health+ IME